2,658 results on '"Gale, Robert Peter"'
Search Results
2. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
3. Measurable residual disease (MRD)-testing in haematological and solid cancers
4. Radiation exposure and space exploration
5. Measurable residual disease in haematological and solid cancers
6. Prof. Constance Jean Eaves: Doyenne of Stem Cells. May 22, 1944 – March 7, 2024
7. Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma
8. Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?
9. Correction: To Mars and beyond. Space exploration and space medicine in Leukemia
10. Is myelo-ablative pretransplant conditioning really myelo-ablative: Implications for radiation and nuclear accidents?
11. What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
12. Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics
13. Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
14. Targeting nucleolin improves sensitivity to chemotherapy in acute lymphoblastic leukemia
15. Have we been qualifying measurable residual disease correctly?
16. Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?
17. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia
18. How should we interpret conclusions of TKI-stopping studies
19. Nuclear war and physicians’ social responsibility
20. Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells
21. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia
22. Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia
23. Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia
24. Methodological challenges in the development of endpoints for myelofibrosis clinical trials
25. Chronic myeloid leukaemia: Biology and therapy
26. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults
27. Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
28. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
29. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy
30. Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny
31. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
32. Validation of the imatinib-therapy failure model
33. Can Immune Therapy Cure Acute Myeloid Leukemia?
34. Using real-world evidence in haematology
35. Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma
36. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
37. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
38. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
39. Correction: Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?
40. The role of randomized controlled trials, registries, observational databases in evaluating new interventions
41. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
42. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
43. Thalassaemia in China
44. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
45. A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma
46. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
47. Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission
48. Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma
49. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
50. DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10–FGFR2 signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.